Clinical Trial

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Study acronym: ACCESS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Protocol Amendment History 42 amendments
This ClinicalTrials.gov record has been amended 42 times since 2021-05-26; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2025-07-25
Status change: Not Yet Recruiting → Recruiting 2021-09-09
Trial Details
NCT Number NCT04904588
Lead Sponsor Center for International Blood and Marrow Transplant Research
Collaborators: National Marrow Donor Program
Conditions Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Enrollment 300 participants
Start Date 2021-09-30
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-18